z-logo
open-access-imgOpen Access
Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer
Author(s) -
Kenneth H. Kim,
Danijela Jelovac,
Deborah K. Armstrong,
Benjamin J. Schwartz,
Susan C. Weil,
Charles Schweizer,
Ronald D. Alvarez
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/8wrf-r472
Subject(s) - carboplatin , ovarian cancer , doxorubicin , platinum , medicine , epithelial ovarian cancer , oncology , pharmacology , cancer research , cisplatin , cancer , chemotherapy , chemistry , biochemistry , catalysis

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom